Sourasky Medical Centre

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma2 trials
• Endometrial cancer1 trial
• Gastric and oesophageal cancer1 trial
• Liver and biliary tract cancer1 trial
• Lupus (SLE)1 trial

Phase

• Phase 1/23 trials
• Phase 32 trials
• Phase 11 trial

Status

• Active, not recruiting3 trials
• Recruiting2 trials
• Terminated1 trial

Lead sponsor

• Hoffmann-La Roche4 trials
• BioNTech SE1 trial
• Genentech, Inc.1 trial

Running trials

• Recruiting

  A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  NCT06340568· Phase 3· BioNTech SE· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

  NCT05535244· Phase 1/2· Hoffmann-La Roche· Source

• Recruiting

  A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT04910568· Phase 1· Genentech, Inc.· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

  NCT04524871· Phase 1/2· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

  NCT04221477· Phase 3· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Endometrial cancer1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Terminated

  A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

  NCT03281369· Phase 1/2· Hoffmann-La Roche· Source